Bernstein raised the firm’s price target on Natera (NTRA) to $135 from $125 and keeps an Outperform rating on the shares. With the large, diversified tools companies taking a hit this earnings season, the firm sees the diagnostics names as the safe place to be in the sector. Broadly, reimbursement tailwinds from the biomarker bills continue to help ASPs in the sector, with California’s bill now live and the introduction of a new bill from Hawaii. On the regulatory front, the FDA LDT regulation was enacted in Q2, though legal challenges have been mounting as expected, Bernstein adds.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTRA:
- Natera price target raised to $150 from $145 at Canaccord
- Natera price target raised to $150 from $140 at Leerink
- Craig-Hallum says buy CareDx as Natera drops pursuit of infringement claims
- Natera says court orders injunction against NeoGenomics’ accused RaDaR assay
- Natera price target raised to $150 from $135 at BTIG